Dunross & Co AB is the original company, created in 1990. This Swedish company situated in Gothenburg, invests in equities and bonds in Breakout Nations. The company also provide supporting services, such as accounting, IT and research. At present the company employs nine persons, located in the central city of Gothenburg.
Dunross Asia Pte. Ltd.
Dunross Asia, located in Singapore is a subsidiary to Dunross Investment Ltd. It is a research company, and gives us physical presence in Asia, which is our main geographical focus, constituting approximately 65 percent of our total equity investments. During the years several analysts at Dunross have been employed here, totally five persons, but for the moment one analyst is employed.
Dunross & Co Holding Ltd.
Dunross & Co Holding Ltd., is the Dunross group’s holding company, situated in Paphos, Cyprus. The company is dedicated in managing bonds in Breakout Nations and is also an active real estate development company focused on the central part of Paphos. The first project started in 2017 and several new projects are under investigation. The company has four persons employed and is located on 46 Ioanni Agroti in Paphos.
Dunross & Co S.A.
Dunross & Co S.A. is a self-managed Special Investment Fund in Luxembourg, located in the central city of Luxembourg. The company is supervised by CSSF (Commission de Surveillance du Secteur Financier) in Luxembourg. The company invests in equities in Breakout Nations and has 10 persons employed. The sole investor in the Fund is Dunross & Co Holding Ltd.
Ägir Invest AB
Ägir Invest is a subsidiary to Dunross & Co AB and invests in Private Equity in Swedish companies. We take advantage of our ability and experience of creating great companies. Dunross was part of many success stories especially during the period 1989 to 2004. The most important investment in Ägir Invest is Cellectricon AB. The company is located at Kungstorget 14, Gothenburg.
Cellectricon AB is owned by Ägir Invest AB (96 percent), and is a biotechnology company with patented unique technology, enhancing pharmaceutical companies’ possibilities to develop new drugs, especially regarding diseases in areas such as pain and central nervous system, Alzheimer’s, Parkinson’s and Hutchinson’s. The company has 11 persons employed and is situated just outside Gothenburg, in Mölndal